DEPO

[bourkeco]

I have been in since Jan. 05 @4.75 I thought it would make a moove sooner but it on the move now.
any opinions ?

[bourkeco]

I have been in since Jan 05 and the run has just started and the news is flowing. I don't know how to do all the cool charts and such but I do think this stock has a huge upside.
Thanks for any opinions
Scott

[bourkeco]

I would love to have some input on this one.
Thanks
Scott

[Stocksquire]

Nice news today, and possibly in breakout mode:

Press Release Source: Depomed, Inc.

Depomed Announces Positive Results of Phase II Clinical Trial for Gabapentin GR(TM) in Postherpetic Neuralgia
Wednesday January 4, 8:00 am ET


MENLO PARK, Calif.--(BUSINESS WIRE)--Jan. 4, 2006--Depomed, Inc. (Nasdaq:DEPO - News) today announced statistically significant safety and efficacy benefits of its Gabapentin GR extended release tablets to treat patients with postherpetic neuralgia, a long-lasting pain condition caused by nerve damage during a shingles, or herpes zoster, viral infection.
The randomized, double-blind, placebo controlled trial involved 158 postherpetic neuralgia patients. Patients were randomized to one of three treatment groups over four weeks of treatment: placebo and 1800 mg total daily dose of Gabapentin GR given once- and twice-daily.

Reductions in average daily pain scores were statistically significant with twice-daily Gabapentin GR from week two to the end of treatment based on the Likert pain scale. Clinically significant improvements in the score were observed with mean change from baseline to study end of -2.24 compared to -1.29 for placebo (p= 0.014). The secondary endpoint of sleep interference was also statistically significantly different with Sleep Interference Scores reduced by -2.28 with Gabapentin GR compared to -1.16 with placebo (p=.006). In addition, in the Clinical Global Impression of Change, a scale used by physicians for overall assessment of patient improvement, 52.3% of patients taking Gabapentin twice daily were "very much improved" or "much improved" compared to only 25% of the patients who received placebo.

For once daily Gabapentin GR, there was also a trend in pain improvement with a reduction in mean daily pain score of -1.93 with Gabapentin GR compared to -1.29 with placebo (p= 0.089). Sleep Interference Scores were reduced by -1.94 compared to -1.16 with placebo (p=0.048).

"As we expected, these data strongly support twice daily Gabapentin GR and are very encouraging for once daily use for the treatment of postherpetic neuralgia," said John W. Fara, Ph.D., chairman, president and chief executive officer of Depomed. "We look forward to finalizing our Phase III program to solidly position our product as a more convenient alternative for longer, more extended pain relief. We look forward to beginning pivotal trials in the first half of this year."

There were no serious adverse events associated with Gabapentin GR. The most common side effect observed was dizziness, which is commonly associated with gabapentin.

Bret Berner, Ph.D., vice president Product Development of Depomed, added, "From an efficacy standpoint, the reductions in pain reported with Gabapentin GR once- and twice- daily are comparable to reported historical data for total daily doses of 1800 to 3600 mg of Neurontin® given three- times daily. In addition, we observed sustained pain relief with Gabapentin GR without sedating patients. It is rewarding to see such strong pain relief trends in this Phase II study size and design which has given us insight to power our Phase III trials."

Postherpetic Neuralgia

Postherpetic neuralgia (PHN) is a persistent pain condition caused by nerve damage during a shingles, or herpes zoster, viral infection. PHN afflicts approximately one in five patients diagnosed with shingles. The incidence increases in elderly patients with 75 percent of those over 70 years old developing PHN. The pain associated with PHN reportedly can be so severe that patients are unable to resume normal activities for months. Since there is no cure for PHN, treatments are focused on relieving pain.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once daily administration and reduced gastrointestinal side effects, improving patient convenience, compliance and pharmacokinetic profiles. Proquin® XR (ciprofloxacin hydrochloride) once daily, extended-release tablets have been approved by the FDA for the treatment of uncomplicated urinary tract infections. In addition, regulatory applications for once daily Glumetza(TM) (Metformin GR®) for the treatment of Type II diabetes have been approved in the U.S. and Canada. The company is also conducting a Phase II trial in post herpetic neuralgia with their product, Gabapentin GR. Additional information about Depomed may be found at its web site, www.depomedinc.com.

Neurontin® is a registered trademark of Pfizer Inc.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



Contact:
Depomed, Inc.
Sylvia Wheeler, 650-462-5900

--------------------------------------------------------------------------------
Source: Depomed, Inc.

[akclide]

Depo is looking good.getting a nice bounce off 50 dma.market cap 154.96m.Cash 33.6 m.Looks good for a short term run

[cipisek]

News http://biz.yahoo.com/bw/070430/20070430005014.html?.v=1

[setravis]

"DEPO" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                                             
All history on a stock pick in 1 thread is awesome.                                                
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.                                   
Thank You....and good luck with all your trades....make some $$$             



Here is today's chart.......

[cipisek]

Hi
http://biz.yahoo.com/ap/070508/earns_depomed.html?.v=1
Today support 3.30, resistance 3.66

[cipisek]

Hi
from: http://biz.yahoo.com/bw/070521/20070521006464.html?.v=1
Press Release Source: Depomed, Inc.


Depomed to Present at the Bank of America 2007 Healthcare Conference
Monday May 21, 7:03 pm ET


MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO - News) today announced that Executive Vice President and Chief Operating Officer Carl Pelzel, will present on Friday, June 1, 2007 at 8:40 a.m. PST during the Bank of America 2007 Healthcare Conference to be held in Las Vegas.
Interested parties can access a live, or archived, webcast of the presentation at http://www.veracast.com/webcasts/bas/healthcare07/id28302302.cfm. The call will also be available and archived on the company's website at www.depomedinc.com.

About Depomed

Depomed, Inc., is a specialty pharmaceutical company with two approved products on the market and multiple product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm(TM) drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Glumetza(TM) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is being marketed in the United States by King Pharmaceuticals and in Canada by Biovail Corporation. ProQuin® XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is marketed by Esprit Pharma. Product candidate Gabapentin GR(TM) is currently in Phase 3 and Phase 2 clinical development for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, respectively. A Phase 2 clinical trial of Gabapentin GR in menopausal hot flashes is expected to begin in the second quarter of 2007. Additional information about Depomed may be found on its web site, www.depomedinc.com.

Today: support 3.95, resistance 4.15

[cipisek]

Hi

today: support 4.01, resistance 4.35

[cipisek]

Hi
from: http://www.rttnews.com/sp/breakingnews.asp?date=06/13/2007&item=109&vid=0

DepoMed Begins Dosing Patients In Phase 2 Trial For Gabapentin GR - Update [DEPO]

6/13/2007 5:15:27 PM DepoMed Inc. (DEPO), a specialty pharmaceutical company, on Wednesday said it has begun dosing patients in Phase 2 trial for Gabapentin GR indicated for the treatment of menopausal hot flashes.

The Phase 2 trial is a double-blind, placebo-controlled, multi-center study, involving about 108 menopausal women experiencing recurrent moderate to severe hot flashes.

The primary endpoint of the trial is the frequency and severity of hot flashes, relative to baseline. Secondary endpoints include the efficacy of Gabapentin GR relative to placebo based on changes from baseline to the end of each treatment period, average daily frequency and severity score of hot flashes and sleep quality.

Gabapentin GR is an investigational, extended release formulation of gabapentin, an FDA-approved drug for the treatment of seizures and postherpetic neuralgia.

DEPO closed Wednesday's regular trading session at $4.46, up 15 cents or 3.48%.

Today: support 4.23, resistance 4.61, opinion BUY